Short-acting Beta Agonists Market size is expected to reach USD 2.07 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e. 2024-2036. In the year 2023, the industry size of short-acting beta agonists was USD 736 Million. The escalating prevalence of respiratory disorders worldwide is propelling the market’s growth. With 454.6 million cases (417.4–499.1) worldwide, chronic respiratory disorders ranked as the third most common cause of mortality in 2019. They were responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) worldwide. As conditions like asthma and chronic obstructive pulmonary disease(COPD) become more widespread, the demand for quick-relief medications, such as SABAs, continues to surge. As observed by Research Nester analysts, globally, the prevalence of COPD was predicted to be 10.6% in 2020 for both males and females, or 480 million cases. This driver is fuelled by environmental factors, lifestyle changes, and an aging population, necessitating effective bronchodilators for immediate symptom relief. As a result, pharmaceutical companies are witnessing increased demand for SABAs, positioning them as a pivotal solution in addressing the rising global burden of respiratory diseases.
In addition, when it comes to death rates, chronic obstructive pulmonary disease (COPD) is ranked third worldwide. The increasing prevalence of lung illnesses worldwide is predicted to drive short-acting beta agonists market expansion. People who currently reside in or were raised in urban regions are more prone to experience these illnesses.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 9% |
|
Base Year Market Size (2023) |
~ USD 736 Million |
|
Forecast Year Market Size (2036) |
~ USD 2.07 Billion |
|
Regional Scope |
|
Dosage Form (Injectable, Solution, Tablet, Syrup)
The solution segment is predicted to account for 42% share of the global short-acting beta agonists market. The segment’s dominance is primarily due to the nature of respiratory conditions like asthma and COPD, where direct delivery to the lungs provides rapid relief. Between 2001 and 2021, the prevalence of adult asthma increased from 6.9% to 8.0%. Inhalable forms offer a quick onset of action, targeting the affected airways directly. While injectable forms, tablets, and syrups may have their applications, inhalable solutions and aerosols are generally preferred for their effectiveness, convenience, and reduced systemic side effects. Patients find inhalable forms more user-friendly and compliant, contributing to their widespread adoption. Additionally, advancements in inhalation device technology further enhance the appeal of these dosage forms, reinforcing their anticipated majority market share.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores)
Retail pharmacies segment is anticipated to hold the majority of the revenue share in the global short-acting beta agonists market. This is attributed to the widespread accessibility of retail pharmacies, making SABA medications readily available to a larger patient population. Retail pharmacies offer convenience, ease of access, and personalized consultation services, promoting patient adherence to respiratory treatments. Additionally, the established presence of retail chains and their ability to provide immediate relief medications aligns with the urgent and episodic nature of conditions like asthma, contributing to the expected dominance of this distribution channel.
Our in-depth analysis of the global short-acting beta agonists market includes the following segments:
|
Dosage Form |
|
|
Distribution Channel |
|
|
Application |
|
North American Market Forecast
North America region is estimated to dominate the global short-acting beta agonists market, accounting for 35% of the revenue share. The region's growth is attributed to the presence of key players in the region. The market is influenced by factors such as the increasing prevalence of respiratory disorders, advancements in inhalation technology, and a growing awareness of respiratory health. Regulatory approvals, generic competition, and regional healthcare policies significantly impact market dynamics. As a crucial component of respiratory care, the North American Short-acting Beta-Agonists market continues to evolve with a focus on innovation, accessibility, and patient-centric solutions. For instance, in the United States, chronic lung diseases such as asthma and COPD, which encompass emphysema and chronic bronchitis, affect about 34 million individuals.
European Market Statistics
European short-acting beta agonists market is estimated to hold a significant revenue share. The market for Short-acting Beta Agonists (SABAs) is influenced by a variety of factors, including the growing prevalence of respiratory disorders, advancements in inhalation technologies, and regulatory approvals. Other factors such as generic competition, regional variations, and healthcare policies also impact market trends. The European SABA market is highly focused on innovation in inhalation therapy and patient-centric solutions. With an emphasis on improving respiratory health and enhancing treatment accessibility, the market is constantly evolving to meet the diverse needs of patients across the region. This focus on innovation and patient-centric solutions has helped to establish Europe as a leader in the global SABAs market.
Bayer AG
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?